Skip to content
Yog Pharma
Central nervous systemAntiepileptic (SV2A ligand)

Levetiracetam is an antiepileptic (SV2A ligand) indicated for partial-onset, myoclonic and primary generalized tonic-clonic seizures. We supply it to US manufacturers of tablets, extended-release tablets, oral solution and injection.

CAS102767-28-2170.2 g/molC8H14N2O2
2D structure of Levetiracetam.

Data from PubChem (CID 5284583) and FDA’s substance registry

CAS number

102767-28-2

Molecular formula

C8H14N2O2

Molecular weight

170.2g/mol

FDA UNII

IUPAC name

(2S)-2-(2-oxopyrrolidin-1-yl)butanamide

InChIKey

HPHUVLMMVZITSG-LURJTMIESA-N

Appearance
White to off-white crystalline powder with a faint odor and a bitter taste.
Solubility
Very soluble in water (104 g per 100 mL). Freely soluble in chloroform and methanol, soluble in ethanol and sparingly soluble in acetonitrile.

Typical description, from FDA-approved labeling and pharmacopoeial monographs. The specification sent with your quote is the controlling document for any source.

Worth settling with your inquiry

The single S-enantiomer; check the limit for the R-enantiomer. Doses run to grams a day, so it is bought in volume.

On the US market

Reference product
KeppraNDA 021035
Approved ANDAs
66 with a marketed product
Approved forms and strengths
  • Tablet 250 mg, 500 mg, 750 mg, 1 g
  • Injection 500 mg/100 mL, 500 mg/5 mL, 1 g/100 mL, 1.5 g/100 mL
  • Extended-release tablet 500 mg, 750 mg
  • Oral solution 100 mg/mL

Single-ingredient products in FDA’s Drugs@FDA database, retrieved November 2026. The brand name belongs to its owner and identifies the reference product only.

Grade

USP or Ph. Eur. where a monograph exists, or your own specification.

Quantities

From development quantities for formulation work to commercial supply.

Packaging

To the manufacturer’s standard, typically fiber or HDPE drums with double polyethylene liners.

Regulatory filings

US DMF and CEP availability depends on the source. We confirm the filing status in writing with the quotation.

Documents available with a quote

  • Specification and certificate of analysis
  • Safety data sheet
  • Method of analysis
  • DMF letter of authorization, where a US DMF is filed
  • GMP certificate and inspection history of the site
  • Residual solvents and elemental impurities statements
  • Nitrosamine risk assessment
  • TSE/BSE statement

Need something else for your QA file? Email info@yogpharma.com